KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to 62.44%.

  • Royalty Pharma's EBITDA Margin rose 15400.0% to 62.44% in Q4 2025 from the same period last year, while for Dec 2025 it was 65.58%, marking a year-over-year increase of 84800.0%. This contributed to the annual value of 65.58% for FY2025, which is 84800.0% up from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's EBITDA Margin is 62.44%, which was up 15400.0% from 70.11% recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's EBITDA Margin registered a high of 130.17% during Q3 2024, and its lowest value of 85.31% during Q4 2022.
  • For the 5-year period, Royalty Pharma's EBITDA Margin averaged around 46.43%, with its median value being 48.21% (2023).
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -1119600bps in 2022, then skyrocketed by 1881400bps in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's EBITDA Margin stood at 26.65% in 2021, then plummeted by -420bps to 85.31% in 2022, then skyrocketed by 221bps to 102.82% in 2023, then tumbled by -41bps to 60.9% in 2024, then grew by 3bps to 62.44% in 2025.
  • Its last three reported values are 62.44% in Q4 2025, 70.11% for Q3 2025, and 36.26% during Q2 2025.